Holen Sie sich die Stockscreener-App
0.0272
0.86%
-0.0193
Handel nachbörslich:
.03
0.0028
+10.29%
Schlusskurs vom Vortag:
$0.0465
Offen:
$0.0272
24-Stunden-Volumen:
374
Relative Volume:
6.24
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.68M
KGV:
-0.0144
EPS:
-1.89
Netto-Cashflow:
$-48.93M
1W Leistung:
-0.86%
1M Leistung:
-43.95%
6M Leistung:
-23.49%
1J Leistung:
-96.95%
1-Tages-Spanne:
$0.0272
$0.0272
1-Wochen-Bereich:
$0.0272
$0.0272
52-Wochen-Spanne:
$0.0272
$0.0272
Galera Therapeutics Inc Stock (GRTX) Company Profile
Firmenname
Galera Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.0272 | 0 | 0 | -69.68M | -48.93M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-10-19 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-12-02 | Eingeleitet | BTIG Research | Buy |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Buy |
| 2019-12-02 | Eingeleitet | Citigroup | Buy |
| 2019-12-02 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics extends agreement deadline - Investing.com Australia
Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com
Galera Therapeutics holds annual stockholder meeting By Investing.com - Investing.com South Africa
Galera Therapeutics holds annual stockholder meeting - Investing.com India
Oral Mucositis Market to Expand Significantly by 2034, States DelveInsight Report - EIN News
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment - MSN
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MyChesCo
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
Galera Therapeutics director Nancy Chang buys $499,978 in stock By Investing.com - Investing.com South Africa
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics director Nancy Chang buys $499,978 in stock - Investing.com
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition - TipRanks
Oncotelic Therapeutics Implements PDAOAI Platform - The Manila Times
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - The Bakersfield Californian
Galera Therapeutics Acquires Nova Pharma, Pivots to Breast Cancer Drug Development with $3M Investment - StockTitan
Galera Therapeutics, Inc. acquired Nova Pharmaceuticals, Inc. - Marketscreener.com
Guardian Capital Partners Acquires Team LINX to Drive Growth in Technology Infrastructure - MyChesCo
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Twelve option delistings on December 23rd - TipRanks
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MyChesCo
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
The 2024 Biotech Graveyard - Fierce Biotech
Galera stockholders reject liquidation plan - Investing.com
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MyChesCo
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire
Finanzdaten der Galera Therapeutics Inc-Aktie (GRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.23%
Kapitalisierung:
|
Volumen (24h):